Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. is holding its 2026 annual stockholder meeting virtually on June 3, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 10, 2026 can vote on electing two Class I directors, Teddie Wardi and Tyler Sloat, to terms ending at the 2029 meeting and on ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights that a majority of directors and all board committees are independent, and describes extensive risk oversight, cybersecurity, and executive compensation programs. The proxy also details significant 2025 equity-based pay for senior executives and the structure of director retainers and RSU grants.
Hinge Health, Inc. director Tyler Sloat acquired 68 shares of Class A Common Stock through the settlement of fully vested restricted stock units on April 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program. Following this equity grant, Sloat directly holds 9,964 Class A shares.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg converted 50,000 shares of Class B Common Stock into 50,000 shares of Class A Common Stock and then sold all of those Class A shares in open-market transactions.
The sales covered 49,332 shares at a weighted average of $38.448 and 668 shares at a weighted average of $39.0167, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. Following these trades, he held no Class A shares directly but continued to hold 1,793,102 Class B shares directly, plus additional Class B shares through a GRAT and a family trust that are convertible into over 1.47 million Class A shares. The filing also notes 944,250 performance stock units held by Mecklenburg, which are excluded from the share totals.
Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition. On this Form 4, 831 shares of Class A Common Stock were withheld and cancelled at a value of $38.56 per share to cover federal and state tax withholding from the vesting of restricted stock units. After this transaction, Pursley directly holds 731,273 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a disposition of 4,614 shares of Class A Common Stock on a tax-withholding basis. The shares were relinquished to the company at $38.56 per share to cover federal and state tax obligations from vesting restricted stock units. Following this exempt transaction under Section 16b-3(e), Budge directly holds 396,813 shares of Class A Common Stock.
Hinge Health Inc disclosure: The Vanguard Group filed an amendment reporting 0 shares beneficially owned of Hinge Health common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The report states Vanguard and related investment vehicles retain the right to receive dividends or sale proceeds where applicable; no single other person holds >5% of the class according to the filing.
Hinge Health, Inc. Chief Financial Officer James Budge reported selling a total of 11,006 shares of Class A Common Stock on March 23, 2026 in three open-market transactions. The reported weighted average sale prices were $41.2858, $42.4514 and $42.8023 per share, each with specified intraday price ranges.
These sales were effected under a Rule 10b5-1 trading plan adopted by Budge on June 12, 2025, indicating they were pre-arranged. Following the transactions, he directly owns 401,427 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. president James Pursley sold 15,000 shares of Class A Common Stock in open-market transactions. The sales on March 23, 2026 were split into three trades: 2,256 shares at $41.2126, 9,838 shares at $42.3571, and 2,906 shares at $42.7538.
These trades were executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. After the transactions, Pursley directly owned 732,104 shares of Hinge Health Class A Common Stock.
HNGE affiliate reported a proposed sale of securities under a Form 144. The filing lists a 10b5-1 sale by James Budge of 14,763 shares on 02/23/2026 with gross proceeds of $580,736.79. The broker is listed as Morgan Stanley Smith Barney LLC.